Startups
Feldan Therapeutics
Québec City, Québec, Canada
Feldan Therapeutics is the operating name of Feldan Bio Inc., a clinical-stage biotechnology company based in Québec City, Canada. Its GLEIF legal-entity record identifies Québec registration 1164440852 and incorporation on 15 May 2007. The company develops intracellular delivery technologies and investigational treatments for skin and lung diseases. Its proprietary Feldan Shuttle is a peptide-based platform designed to deliver therapeutic cargo, including antisense oligonucleotides, into cells and overcome endosomal entrapment. This drug-delivery platform makes Feldan relevant to deep technology and biotechnology. The current company directory describes FLD-103 as an investigational intralesional, non-surgical treatment for basal cell carcinoma in a Phase 1 trial at sites in the United States and Australia; its March 2026 project announcement refers to the program as Phase 1/2a. The Australian trial is overseen by wholly owned Feldan Australia Pty Ltd. FLD-201 is an inhaled investigational therapy for mucus-driven respiratory diseases, including non-cystic fibrosis bronchiectasis and chronic bronchitis, in preclinical development. Separate collaborations investigate pulmonary delivery, genome-editing cargo and integration of the Shuttle with lipid nanoparticles for mRNA delivery. These descriptions concern investigational programs and company-reported delivery capabilities. François-Thomas Michaud is CEO and co-founder. The current public directory names 35 staff members and seven board members, including the CEO in both groups. Financing includes a 2018 Series A, an initial Series B closing in June 2023 and a completed USD21M Series B announced in September 2024. Strategic investments by Linearis Ventures and Zynext Ventures were announced in February and April 2025, respectively, with undisclosed amounts. Research awards and collaborative project budgets are documented separately from equity funding.
Founded 2007
Team
 Al Halifa SoultanDirector R&D – Drug Delivery Technologies |
 Alain HoudeLaboratory Technician |
 Alex-Anne AllaireCommunications & Administration Associate |
 Anna Xue ChengDirector R&D – Pulmonary Drug Delivery |
 Anne-Marie DuperréResearch Specialist Iii |
 Annie BoucherClinical Trial Assistant |
 Catherine LippéVP - Clinical Development |
 Christine HurleyDirector - Quality Assurance & Compliance |
 David GuayVp - Innovation & Technology |
 David J. MazzoChairman |
 Elisabeth Sandoval LittleBoard Member |
 Eric CarterBoard Member |
 Flora Peillard FiorenteStrategic Development Specialist |
 François-Thomas MichaudChief Executive Officer & Co-Founder · Board Member |
 Félix BéginMaster'S Student |
 Gaëlle BourriquenResearch Specialist Ii |
 Imen ArbiResearch Specialist I |
 Isabelle DeschênesAccounting and Logistic Coordinator |
 Jamie StiffBoard Member |
 Janick Sirois-FraserFinancing & Business Development Associate |
 Jean-Pascal Lepetit-StoffaesDirector - Strategic Development |
 Jonathan RogerClinical Study Manager |
 Julie PhilippeAdministrative Assistant |
 Kelly TanguayResearch Specialist I |
 Luis SorrozaResearch Specialist Ii |
 Marie-Michèle LabrecqueAssociate Clinical Study Manager |
 Mario HarveySenior Research Specialist |
 Maud AugerResearch Specialist Ii |
 Maxime HervaultResearch Specialist Ii |
 Meriem BenchabaneVp - Strategic Development & Operations |
 Mia PelletierPhd Student |
 Nadine BrahitiProject Manager - Drug Delivery Technologies |
 Nancy MessierSenior Vp - Drug Discovery |
 Nathalie ChauretBoard Member |
 Nayeli EsparzaPostdoctoral Fellow |
 Olympe Garnier--LeymoneriePhd Student |
 Paul F. TruexBoard Member |
 Pierre-Alain MoissetDirector - Drug Development |
 Stéphanie LevesqueDirector - Corporate Governance & Communications |
 Vanessa ThébergeProject Manager - Drug Discovery |
 Vincent MénardChief Financial Officer (CFO) |